58.21
58.21 (0%)
As of Apr 17, 2025
INCYTE CORP [INCY]
Source:
Company Overview
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations.
| Country | United States |
| Headquarters | wilmington, delaware |
| Phone Number | 3024986700 |
| Industry | services |
| CEO | Hervã Hoppenot |
| Website | www.incyte.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $4,241.2 |
| Operating Profit | $61.4 |
| Net Income | $32.6 |
| Net Cash | $-1,525.8 |
Profit Ratios
| Gross Margin | $3,929.1 |
| Operating Margin | 1.5 |
| Profit as % of Revenues | 12,047.1% |
| Profit as % of Assets | 0.5% |
| Profit as % of Stockholder Equity | 1% |
Management Effectiveness
| Return on Equity | 1% |
| Return on Assets | 0.6% |
| Turnover Ratio | 69.4% |
| EBITA | $61.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $5,444.3 |
| Total Liabilities | $1,996.7 |
| Operating Cash Flow | $335.3 |
| Investing Cash Flow | $157.5 |
| Financing Cash Flow | $-2,021.5 |
